List of Excipients in Branded Drug KAZANO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Takeda Pharmaceuticals America Inc	KAZANO	alogliptin and metformin hydrochloride	64764-335	CELLULOSE, MICROCRYSTALLINE	2026-07-27
Takeda Pharmaceuticals America Inc	KAZANO	alogliptin and metformin hydrochloride	64764-335	CROSPOVIDONE	2026-07-27
Takeda Pharmaceuticals America Inc	KAZANO	alogliptin and metformin hydrochloride	64764-335	FERRIC OXIDE YELLOW	2026-07-27
Takeda Pharmaceuticals America Inc	KAZANO	alogliptin and metformin hydrochloride	64764-335	HYPROMELLOSE 2910	2026-07-27
Takeda Pharmaceuticals America Inc	KAZANO	alogliptin and metformin hydrochloride	64764-335	MAGNESIUM STEARATE	2026-07-27
Takeda Pharmaceuticals America Inc	KAZANO	alogliptin and metformin hydrochloride	64764-335	MANNITOL	2026-07-27
Takeda Pharmaceuticals America Inc	KAZANO	alogliptin and metformin hydrochloride	64764-335	POVIDONE	2026-07-27

KAZANO Excipient Strategy and Commercial Opportunities

Last updated: August 26, 2026

KAZANO is an immediate-release fixed-dose combination of alogliptin benzoate and metformin hydrochloride for type 2 diabetes. Its commercial value is driven less by novel excipient chemistry than by formulation execution: maintaining dose uniformity across a high-load metformin tablet, controlling alogliptin degradation, preserving dissolution, and improving tolerability and manufacturability.

The strongest excipient opportunities are generic or lifecycle formulations that reduce tablet size, improve swallowability, address gastrointestinal intolerance, enable modified release, or support differentiated regulatory filings. KAZANO is a small-molecule product, so biosimilar competition is not relevant. Generic substitution, formulation patents, method-of-use patents, and manufacturing know-how are the principal competitive issues.

What is KAZANO and what excipients does it contain?

KAZANO combines alogliptin benzoate, a dipeptidyl peptidase-4 inhibitor, with metformin hydrochloride, a biguanide antihyperglycemic agent. The U.S. product is supplied as immediate-release tablets in 12.5 mg/500 mg, 12.5 mg/1,000 mg, and 12.5 mg/850 mg strengths.[1]

The listed inactive ingredients include excipients used for compression, disintegration, lubrication, and film coating. Product labeling identifies the core formulation as containing mannitol, povidone, crospovidone, and magnesium stearate. The film coating contains standard coating materials, including hypromellose, titanium dioxide, talc, and colorants, depending on tablet strength.[1]

Formulation component	Principal function	Commercial relevance
Mannitol	Diluent and compression aid	Can improve mouthfeel and tablet handling; may increase formulation cost versus lactose or dibasic calcium phosphate
Povidone	Binder	Supports granule strength and content uniformity
Crospovidone	Superdisintegrant	Promotes rapid tablet breakup and dissolution
Magnesium stearate	Lubricant	Supports ejection and manufacturing efficiency; excessive levels can slow dissolution
Hypromellose	Film former	Protects the tablet and improves appearance
Titanium dioxide and colorants	Opacifier and identification system	Supports strength differentiation and product recognition
Talc	Coating aid	Improves coating processability

The formulation is designed for immediate release rather than prolonged delivery. The excipient system must accommodate metformin hydrochloride’s high dose and hydrophilic character while maintaining rapid release of alogliptin.

How does KAZANO’s active pharmaceutical ingredient profile affect excipient selection?

Metformin hydrochloride is the dominant formulation constraint. A 500 mg or 1,000 mg metformin dose creates a large tablet mass before adding alogliptin, binders, disintegrants, lubricants, and coating materials. Tablet size, tensile strength, friability, and swallowability are therefore central development risks.

Alogliptin is present at a much lower dose but remains important for blend uniformity. Low-dose alogliptin distribution across a high-dose metformin matrix requires control of particle size, premixing, segregation, and granulation behavior. A formulation can meet average assay requirements while still failing content-uniformity or blend-uniformity expectations if the active ingredients have materially different particle characteristics.

The principal technical objectives are:

1. Maintain alogliptin uniformity in a metformin-dominant blend.
2. Limit lubricant overmixing that could retard dissolution.
3. Avoid excessive tablet hardness that delays disintegration.
4. Control moisture and thermal exposure during processing.
5. Preserve comparable dissolution profiles across strengths.
6. Manage tablet size and coating weight for patient acceptability.

A formulation developer may select wet granulation, dry granulation, or direct compression depending on the particle properties of the active ingredients and the desired process profile. Direct compression may reduce process steps but can increase segregation risk. Wet granulation can improve blend uniformity and compactability but introduces water and drying exposure. Dry granulation can reduce moisture exposure while increasing equipment and density-control requirements.

What excipient strategy is most suitable for a generic KAZANO product?

The lowest-risk strategy is an immediate-release formulation using widely accepted compendial excipients and a process designed to match the reference product’s dissolution behavior. A generic manufacturer does not need to copy the qualitative excipient composition exactly in the United States, but the formulation must demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA pathway.[2]

A practical baseline formulation would retain:

• A high-capacity diluent such as mannitol, microcrystalline cellulose, or a combination.
• Povidone or a comparable binder.
• Crospovidone or croscarmellose sodium as a superdisintegrant.
• Magnesium stearate or another established lubricant at a controlled concentration.
• A conventional hypromellose film coat.

A substitution strategy can create cost or performance advantages. Mannitol may be replaced partly or fully by microcrystalline cellulose, lactose, or dibasic calcium phosphate, subject to compatibility, density, compressibility, and dissolution testing. The best choice depends on the manufacturing platform and target tablet weight.

Microcrystalline cellulose can improve compactability and reduce the need for high binder levels. Lactose may lower cost but can create compatibility or moisture-management issues depending on the active ingredients and process. Dibasic calcium phosphate can improve flow and hardness but may increase tablet density and complicate disintegration or dissolution design.

Crospovidone is attractive for rapid disintegration, particularly when the formulation uses a high tablet hardness target. Croscarmellose sodium may offer a cost-effective alternative, although performance depends on intragranular and extragranular placement, particle size, and compression conditions.

What formulations are protected by KAZANO patents?

KAZANO’s commercial protection is primarily associated with the active ingredients, fixed-dose combination, dosing regimen, and product claims rather than with a widely recognized proprietary excipient platform. The principal commercial risk for a generic manufacturer is therefore regulatory and patent-status verification, not an obvious barrier created by the listed excipients.

A complete freedom-to-operate analysis should separate four claim categories:

Fixed-dose combination claims

These claims may cover the combination of alogliptin or an alogliptin salt with metformin, including particular dosage ratios or pharmaceutical compositions.

Method-of-use claims

Claims may cover treatment of type 2 diabetes, glycemic control, use in patients inadequately controlled on metformin, or administration of specific alogliptin/metformin dose combinations.

Formulation claims

These may cover tablet composition, immediate-release performance, particle properties, granulation conditions, or defined excipient ranges. A formulation patent can create risk even when the active-ingredient patent has expired.

Manufacturing claims

Process claims may cover granulation, blending, compression, coating, or production of a pharmaceutical composition containing alogliptin and metformin. Manufacturing claims are particularly relevant when a generic company attempts to reproduce the reference product’s physical characteristics.

Patent status must be confirmed in the relevant jurisdiction and against current Orange Book or national patent registers. FDA’s Orange Book identifies patents and regulatory exclusivities associated with listed drug products, but listing status can change over time.[3]

When does KAZANO lose exclusivity and what is the generic-entry risk?

KAZANO is a small-molecule combination product, so generic entry can occur through an abbreviated new drug application rather than a biosimilar application. A challenger may use Paragraph IV certification if it believes an Orange Book-listed patent is invalid, unenforceable, or not infringed.[2]

The commercial analysis should distinguish:

Risk category	Relevance to KAZANO
Biologic exclusivity	Not applicable
Small-molecule data exclusivity	Potentially applicable at original approval, but generally time-limited
Active-ingredient patent risk	Depends on alogliptin and metformin patent history in each jurisdiction
Combination patent risk	May cover the fixed-dose product or dose ratios
Formulation patent risk	May cover excipient ranges or release properties
Method-of-use risk	May require a skinny-label or carve-out strategy
Orange Book listing risk	Must be checked against the current FDA listing
Manufacturing patent risk	Relevant to process selection and supplier strategy

KAZANO’s high metformin content may make a simple tablet copy less attractive than a formulation using a different granulation platform. A generic company can reduce infringement exposure by changing excipients, manufacturing sequence, coating composition, or tablet architecture, provided it still meets bioequivalence and quality requirements.

What commercial opportunities exist for KAZANO excipient reformulation?

Smaller and more swallowable tablets

The 1,000 mg metformin strength creates a clear tablet-size opportunity. A higher-density formulation, more efficient granulation process, or bilayer architecture could reduce volume. The commercial challenge is maintaining rapid disintegration and acceptable dissolution while increasing tablet density.

A smaller tablet could have value in markets where metformin intolerance and pill burden reduce persistence. The opportunity is strongest if the product can remain an immediate-release, once- or twice-daily fixed-dose combination without adding complex administration requirements.

Extended-release or dual-release products

A modified-release product could target gastrointestinal tolerability, dosing convenience, and reduced peak-related adverse effects. Metformin extended-release products already occupy a mature competitive category, so differentiation would require a credible release profile for both actives and a clear clinical or regulatory rationale.

A dual-release design could release alogliptin rapidly while prolonging metformin delivery. This would require more extensive development than an immediate-release generic and could create new formulation patent space. It also increases dissolution, food-effect, stability, and bioequivalence complexity.

Gastrointestinal-tolerability positioning

Metformin is associated with gastrointestinal adverse effects, including diarrhea, nausea, and abdominal discomfort. Excipient selection alone cannot eliminate active-ingredient intolerance, but particle engineering, granulation, release control, and tablet disintegration can affect local concentration and exposure patterns.

A reformulated product should avoid unsupported tolerability claims unless supported by clinical evidence. From a commercial perspective, the strongest value proposition is a measurable reduction in discontinuation, dosing frequency, or tablet burden.

Pediatric, geriatric, and dysphagia-friendly dosage forms

Potential dosage forms include orally disintegrating tablets, mini-tablets, sprinkle products, and oral granules. These formats face major compatibility and dose-uniformity challenges because metformin’s high dose creates substantial powder mass.

An orally disintegrating formulation may be commercially attractive for selected patients but is difficult to optimize at a 500 mg or 1,000 mg metformin load. Taste masking, moisture control, friability, and mouthfeel become material development issues. A granule or sachet format may provide greater flexibility but would compete with established metformin products and require packaging designed to control moisture.

Excipient-supplier differentiation

Excipient suppliers can pursue commercial opportunities through:

• Direct-compression grades with improved flow and compactability.
• Low-moisture or engineered mannitol grades.
• Co-processed excipients that reduce tablet weight.
• Fast-disintegrating crospovidone or croscarmellose grades.
• Lubricant systems that minimize dissolution retardation.
• Film-coating systems that reduce coating time and solvent or water use.
• Excipient systems designed for continuous manufacturing.

The strongest supplier value proposition is process performance supported by comparative data, not simple substitution of one compendial excipient for another.

How does KAZANO compare with competing diabetes fixed-dose combinations?

KAZANO competes with other DPP-4 inhibitor/metformin combinations, including Janumet, Kombiglyze XR, and Jentadueto. These products differ in active ingredient, release profile, dosing frequency, commercial scale, and remaining intellectual-property exposure.

Product	DPP-4 inhibitor	Metformin form	Main formulation issue
KAZANO	Alogliptin	Immediate-release metformin hydrochloride	High tablet mass and fixed-dose uniformity
Janumet	Sitagliptin	Immediate- or extended-release variants	Large installed base and multiple generic pathways
Kombiglyze XR	Saxagliptin	Extended-release metformin	Controlled release and polymer performance
Jentadueto	Linagliptin	Immediate-release metformin	Dose uniformity and tablet-size management

KAZANO has a smaller commercial footprint than the most established sitagliptin/metformin products. That reduces the addressable market but may also lower competitive intensity for specialized reformulations. A manufacturer with an efficient low-cost platform could target regional markets, hospital tenders, and private-label distribution rather than attempt to displace the largest branded combinations.

What is the FDA regulatory status of KAZANO?

KAZANO was approved by FDA as an oral fixed-dose combination product under NDA 022931.[1] FDA approval establishes the reference product framework for abbreviated generic development. A generic applicant would generally need to demonstrate pharmaceutical equivalence and bioequivalence under an ANDA, subject to the current product-specific guidance and Orange Book status.[2,3]

A reformulation with a materially different release profile, dosage form, or clinical claim may require a different regulatory strategy. The regulatory route depends on the extent of change, the reference product used, the proposed labeling, and whether the product remains pharmaceutically equivalent to the listed drug.

Which companies are positioned to challenge KAZANO?

Potential challengers include established generic manufacturers with metformin manufacturing capacity, DPP-4 inhibitor portfolios, or experience with complex oral solid dosage products. The most credible candidates are companies that can:

• Manufacture high-dose metformin tablets at competitive cost.
• Control low-dose alogliptin blend uniformity.
• Conduct comparative dissolution across multiple strengths.
• Manage Paragraph IV litigation.
• Secure reliable supplies of alogliptin active ingredient and qualified excipients.
• Support regulatory filings in the United States, Europe, and emerging markets.

The opportunity is more attractive for companies with existing diabetes distribution channels. Stand-alone entry would face pricing pressure from metformin generics and competition from other fixed-dose combinations.

What manufacturing and IP barriers affect commercial entry?

The main manufacturing barriers are tablet size, blend segregation, lubrication control, dissolution matching, and stability. The principal IP barriers are current combination, formulation, method-of-use, and process claims.

A robust development program should include:

1. API particle-size and polymorph characterization.
2. Forced-degradation and excipient-compatibility studies.
3. Blend-uniformity mapping for alogliptin.
4. Compression-force and lubricant-level optimization.
5. Comparative dissolution in multiple media.
6. Stability studies under ICH conditions.
7. Patent landscaping across the United States, Europe, Japan, and key emerging markets.
8. A non-infringing process design before pivotal bioequivalence batches.

Excipient changes should be evaluated as part of the patent strategy. A different diluent or disintegrant may reduce formulation overlap, but it does not automatically avoid claims directed to the active combination or method of treatment.

Key Takeaways

• KAZANO is an immediate-release alogliptin benzoate/metformin hydrochloride fixed-dose tablet.
• Its formulation is constrained by the high metformin dose and the low-dose uniformity requirements for alogliptin.
• Mannitol, povidone, crospovidone, magnesium stearate, and conventional film-coating materials form the principal excipient platform identified in U.S. labeling.
• The best generic opportunity is a low-risk immediate-release formulation with controlled tablet size, rapid disintegration, and comparable dissolution.
• The most differentiated opportunities are smaller tablets, modified-release products, dysphagia-friendly formats, and excipient systems that improve continuous or high-throughput manufacturing.
• KAZANO faces generic rather than biosimilar competition.
• Current Orange Book listings, Paragraph IV certifications, patent expiration dates, and litigation records must be reviewed before launch investment or licensing decisions.
• The commercial opportunity is strongest for manufacturers with existing diabetes portfolios and high-dose metformin manufacturing capability.

FAQs About KAZANO Excipient and Commercial Strategy

Can lactose replace mannitol in a KAZANO generic?

Potentially. Lactose can function as a diluent, but compatibility, moisture sensitivity, compactability, dissolution, and stability must be demonstrated. The substitution may reduce cost but could change process performance and tablet properties.

Can KAZANO be reformulated as an extended-release product?

Yes, technically, but an extended-release product would require a new release-control strategy, extensive dissolution work, food-effect assessment, and a regulatory pathway appropriate to the proposed product. It would compete with established metformin extended-release products.

Is KAZANO eligible for a biosimilar application?

No. KAZANO contains chemically synthesized small-molecule active ingredients. Competitive products would generally use generic-drug pathways rather than the biosimilar pathway.

What is the most valuable excipient innovation for KAZANO?

A high-density, directly compressible excipient system that reduces tablet size without slowing disintegration or dissolution has the clearest commercial value. The system must also preserve alogliptin content uniformity in a metformin-dominant blend.

Do excipient changes eliminate KAZANO patent risk?

No. Excipient substitution can reduce overlap with formulation or process claims, but it does not eliminate claims directed to the active combination, dosage regimen, method of treatment, or broader pharmaceutical compositions.

References

1. U.S. Food and Drug Administration. (n.d.). KAZANO (alogliptin benzoate and metformin hydrochloride) tablets, prescribing information. FDA.
2. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA) process. FDA.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
4. European Medicines Agency. (n.d.). Alogliptin-containing medicines: Product information and regulatory records. EMA.
5. International Council for Harmonisation. (2003). Q8(R2): Pharmaceutical development. ICH.